IP Library Granted Patent US 11,045,460
Granted Patent B2
US 11,045,460 · App. 16/698,092 · Granted Jun 29, 2021

Use of Hsp70 as a regulator of enzymatic activity

Inventors: Thomas Kirkegaard Jensen (Rødovre, DK); Marja H. Jaattela (København Ø, DK)
Assignee: Orphazyme A/S
A61K31/4545A61K31/445A61K31/56A61K33/30A61K38/16A61K38/17A61K38/1709A61K38/43A61K38/46A61K38/47A61K45/06C12Y306/01003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,045,460
App. No.
16/698,092
Granted
Jun 29, 2021
Kind
B2
Abstract

The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.

Claims (5)

1. A method for treating Niemann-Pick disease Type C (NPC) in a human comprising orally administering arimoclomol, or a pharmaceutically acceptable salt thereof, to the human.

2. The method of claim 1 , wherein the human is orally administered a daily dosage of arimoclomol, or a pharmaceutically acceptable salt thereof, of from about 1 ug to about 100 mg per kilogram of body weight.

3. The method of claim 2 , further comprising administering Miglustat to the human.

4. The method of claim 2 , further comprising administering enzyme replacement therapy to the human.

5. The method of claim 4 , wherein the enzyme replacement therapy is imiglucerase, agalsidase beta, or agalsidase alpha.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2024
From: KEMPHARM DENMARK A/S
To: ZEVRA DENMARK A/S
Reel/Frame 066539/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2022
From: KEMPHARM, INC.
To: KEMPHARM DENMARK A/S
Reel/Frame 060592/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2022
From: ORPHAZYME A/S
To: KEMPHARM, INC.
Reel/Frame 060592/0646 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2020
From: JENSEN, THOMAS KIRKEGAARD; JAATTELA, MARJA H.
To: ORPHAZYME A/S
Reel/Frame 052593/0815 →
Priority Claims (1)
DK PA200800885 · Jun 26, 2008 · national
Continuity (5)
Continuation 15854352 · Dec 26, 2017
Division 15048483 · Feb 19, 2016
Division 13969944 · Aug 19, 2013
Continuation 13001316
Related Publication 20200121668A1 · Apr 23, 2020